Skip to content

Press Release · Press Releases

Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026

Issued by PR Newswire

No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients; central U.S. ethics committee has approved the protocol and consent documents First patient enrollment continues to be expected in the...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

Sempra Reports Strong Third-Quarter 2026 Results

Advancing 2026 Value Creation Initiatives Updating 2026 GAAP EPS guidance range Guiding to high-end of 2026 adjusted EPS guidance range Announcing expected 20% increase to Oncor's base capital plan SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Sempra (NYSE: SRE) today reported third-quarter...

PR Newswire ·